For Immediate Release – Not for Dissemination in the United States or through U.S. Newswire ServicesGreenville, South Carolina, Jan. 31,…
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval…
Prioritizing Revita’s clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1…
NewGen’s ordinary shares to begin trading on a split-adjusted basis on February 11, 2025BANGKOK, Jan. 31, 2025 (GLOBE NEWSWIRE) --…
BEDMINSTER, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Retrieve Medical, Inc. (www.retrievemedical.com) announces its expansion into the ambulatory care sector…
Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung…
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing,…
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company…
DENVER, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced it has entered…
— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q…